[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345822-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345822-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-targeting-strategies-in-cancer-carbonic-anhydrase-ix-inhibitors-targeting-egfr-or-vegfr-2","Dual Targeting Strategies in Cancer - Carbonic Anhydrase IX Inhibitors Targeting EGFR or VEGFR-2","","Tumor microenvironment shapes tumorigenesis, and hypoxia is a hallmark of many solid tumors with negative prognostic value. Carbonic anhydrases are zinc-containing enzymes frequently overexpressed under acidic and hypoxic conditions, where CA IX supports proliferation, migration, and invasion. VEGFR-2 drives angiogenesis and cancer-related processes, while EGFR is a key receptor tyrosine kinase in cancer progression. This review highlights multifunctional compounds inhibiting CA IX and targeting VEGFR-2 or EGFR to improve efficacy and reduce side effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-targeting-strategies-in-cancer-carbonic-anhydrase-ix-inhibitors-targeting-egfr-or-vegfr-2/345822/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-targeting-strategies-in-cancer-carbonic-anhydrase-ix-inhibitors-targeting-egfr-or-vegfr-2/345822.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is hypoxia important in cancer progression?","Question",{"text":63,"@type":64},"Hypoxia is characteristic of many solid tumors and promotes tumor growth and aggressiveness. It also shifts metabolism toward glycolysis, giving cancer cells a survival advantage.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles do CA IX, VEGFR-2, and EGFR play in tumors?",{"text":68,"@type":64},"CA IX promotes cancer cell proliferation, migration, and invasion, particularly under hypoxic and acidic conditions. VEGFR-2 regulates angiogenesis and related cancer processes, while EGFR is crucial for cancer progression in certain tumor types.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the focus of the review and why are multitarget drugs emphasized?",{"text":72,"@type":64},"The review focuses on novel compounds that inhibit CA IX and target VEGFR-2 or EGFR. Multifunctional multitarget drugs are presented as a promising approach to improve therapeutic effectiveness while reducing side effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345822,1790173948,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nDual Targeting Strategies in Cancer: Carbonic Anhydrase IX Inhibitors Targeting EGFR or VEGFR-2  \nEleftherios Charissopoulos and Eleni Pontiki *  \nAcademic Editor: Bernhard Loll  \nReceived: 25 May 2026  \nRevised: 22 June 2026  \nAccepted: 23 June 2026  \nPublished: 1 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nLaboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [echarise@pharm.auth.gr](echarise@pharm.auth.gr)  \n* Correspondence: [epontiki@pharm.auth.gr](epontiki@pharm.auth.gr); Tel.: +30-2310997671  \nAbstract  \nTumor microenvironment influences the process of tumorigenesis, with hypoxia being a characteristic of many solid tumors and an adverse prognostic factor. Carbonic anhydrases (CAs) are highly efficient zinc-containing enzymes that are overexpressed in many cancers, particularly under acidic and hypoxic conditions. CA IX expression promotes cancer cell proliferation, migration, and invasion. Vascular endothelial growth factor receptor-2 (VEGFR-2) is a tyrosine transmembrane (TM) protein regulating embryonic development, angiogenesis, tissue homeostasis and cancer. Blocking VEGFR-2 signaling is one of the most promising approaches to hindering angiogenesis and growth of cancer cells. The epidermal growth factor receptor (EGFR) is a member of the ERBB family of receptor tyrosine kinases and plays a key role in cancer progression. EGFR is uniquely found in some brain, lung and other cancers. Development of novel strategies to regulate these factors is important for the treatment of tumors. Multifunctional drugs that act on multiple pathways offera promising approach, improving therapeutic effectiveness while reducing side effects. The present review focuses on novel compounds that inhibit CA IX and target VEGFR-2 or EGFR.  \nKeywords: cancer; carbonic anhydrase; VEGFR-2; EGFR; multitarget  \n1. Introduction  \n1.1. Cancer Progression: Hypoxia, Survival, and Angiogenesis  \nCancer is a type of tumor characterized by abnormal cell growth that can invade or spread from its original organ to other parts of the body [1] . Cancer is considered to have enigmatic and complex features, which represent significant obstacles for both researchers and healthcare professionals in finding potential therapeutic strategies [2] . Mutations in genes encoding cell cycle regulatory proteins are primary drivers of carcinogenesis. These defective genes can be inherited or may arise in response to environmental carcinogens [3] . Tumor angiogenesis contributes to the survival and development of tumor cells, and plays a key role in their growth, invasion, and metastasis [4] . Various distinct biological processes occur in tumor vascularization, depending on the tumor type and anatomic location. These processes are regulated by a range of secreted factors and signaling pathways involving non-endothelial cells, such as progenitors or cancer stem cells [5] . Apoptosis is a regulated and evolutionarily conserved cell death program, and cancer cells often shows resistance to apoptosis, endowing them with survival advantages that promote tumor evolution, outgrowth and treatment failure [6] . Moreover, tumor cells can adapt to changes in oxygen tension which gives them ability to develop. Hypoxia is a critical  \nmicroenvironmental factor, which defines a tumor’s growth and aggressiveness (Figure 1) . At low oxygen concentration, cancer cells induce glycolytic metabolism, providing them with significant advantage [7,8] . The lack of novel multitarget drugs combined with the incomplete understanding of the molecular mechanism, is a main obstacle in metastasis prevention and treatment.  \nFigure 1. Schematic representation of the tumor microenvironment and the multi-target effects of du","cbCaibPpYfF4qWro","https://ap.wps.com/l/cbCaibPpYfF4qWro","pdf",3632549,42,"English","# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Cancer Progression: Hypoxia, Survival, and Angiogenesis\n## 1.2. Carbonic Anhydrase IX: Biological Characteristics and Role in Cancer\n### 1.2.1. Carbonic Anhydrase Isoforms and Structural Features of CAIX\n### 1.2.2. Regulation and Functional Role of CAIX in Cancer","[{\"question\":\"Why is hypoxia important in cancer progression?\",\"answer\":\"Hypoxia is characteristic of many solid tumors and promotes tumor growth and aggressiveness. It also shifts metabolism toward glycolysis, giving cancer cells a survival advantage.\"},{\"question\":\"What roles do CA IX, VEGFR-2, and EGFR play in tumors?\",\"answer\":\"CA IX promotes cancer cell proliferation, migration, and invasion, particularly under hypoxic and acidic conditions. VEGFR-2 regulates angiogenesis and related cancer processes, while EGFR is crucial for cancer progression in certain tumor types.\"},{\"question\":\"What is the focus of the review and why are multitarget drugs emphasized?\",\"answer\":\"The review focuses on novel compounds that inhibit CA IX and target VEGFR-2 or EGFR. Multifunctional multitarget drugs are presented as a promising approach to improve therapeutic effectiveness while reducing side effects.\"}]","Dual Targeting Strategies in Cancer - Carbonic Anhydrase IX Inhibitors Targeting EGFR or VEGFR-2 | PDF",1790058993,106,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74cdab0c00040088112b13907dec1fd4.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27e65f677d3b6048e2b9ab6d8a0e5039.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5b0d7edd80d58916a71c4d5505f3cb7.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1f3637550cffe5ea6058f4d062bcf99.webp",980,1385,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40fa9bcacf2a78db4d98d02bbb3560ed.webp",979,1384]